Background There is accumulating evidence for an overly activated immune response in
severe COVID-19, with several studies exploring the therapeutic role of immunomodulation …

As the pandemic progresses, the pathophysiology of coronavirus disease 2019 (COVID‐19)
is becoming clearer and the potential for immunotherapy is increasing. However, clinical …

ABSTRACT BACKGROUND COVID-19 is associated with immune dysregulation and
hyperinflammation. Tocilizumab is an anti–interleukin-6 receptor antibody. METHODS …

Abstract Background Coronavirus disease 2019 (Covid-19) is associated with immune
dysregulation and hyperinflammation, including elevated interleukin-6 levels. The use of …

Introduction Coronavirus disease 2019 (COVID-19) can lead to respiratory failure due to
severe immune response. Treatment targeting this immune response might be beneficial but …

Background High levels of serum interleukin-6 (IL-6) correlate with disease severity in
COVID-19. We hypothesized that tocilizumab (a recombinant humanized anti-IL-6 receptor) …

Background Tocilizumab, an inhibitor of the interleukin-6 receptor, may decrease the
inflammatory response and control the symptoms of severe coronavirus disease 2019 …

BACKGROUND The interleukin-6 receptor antagonist tocilizumab improves outcomes in
critically ill patients with coronavirus disease 2019 (COVID-19). However, the effectiveness …

Background Tocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in
pathogenesis of pneumonia the most frequent cause of death in COVID-19 patients …

Background Tocilizumab is an IL-6 receptor-blocking agent proposed for the treatment of
severe COVID-19. The aim of this systematic review was to describe the rationale for the use …